• Explore /
  • Poster
  • / Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

Abstract Video & Slides Poster

Authors

null

Jessica Cecile Hassel

Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany

Jessica Cecile Hassel , Piotr Rutkowski , Jean-Francois Baurain , Marcus O. Butler , Max Schlaak , Ryan Sullivan , Sebastian Ochsenreither , Reinhard Dummer , John M. Kirkwood , Anthony M. Joshua , Joseph J. Sacco , Alexander Noor Shoushtari , Marlana Orloff , Richard D. Carvajal , Omid Hamid , Shaad Essa Abdullah , Chris Holland , Howard Goodall , Paul Nathan , Sophie Piperno-Neumann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03070392

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9527)

DOI

10.1200/JCO.2021.39.15_suppl.9527

Abstract #

9527

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Alexandra Ikeguchi

First Author: Marlana Orloff

First Author: Richard D. Carvajal

First Author: Hai-Qiang Mai